Meridian Bioscience (NASDAQ:VIVO) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. This is a 27.27 percent decrease over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $67.80 million which beat the analyst consensus estimate of $66.82 million by 1.47 percent. This is a 6.75 percent increase over sales of $63.51 million the same period last year.
Why Are Cannabis Stocks Down? Cantor Fitzgerald Explains Impacts Of Draft Bill & Advises: ‘Use The Weakness’ To Buy Curaleaf, Green Thumb, Trulieve And Cresco
Wednesday was a historic day for the marijuana industry with the unveiling of the highly-anticipated Senate bill that would federally legalize cannabis.
